Abstract:Immunotherapies that target PD-1/PD-L1 axis have shown unprecedented success in awide variety of human cancers. PD-1 is one of the key coinhibitory receptors expressed on T cells upon T cell activation. After engagement with its ligands, mainly PD-L1, PD-1 is activated and recruits the phosphatase SHP-2 in proximity to T cell receptor (TCR) and CD28 signaling. This event results in dephosphorylation and attenuation of key molecules in TCR and CD28 pathway, leading to inhibition of T cell proliferation, activation, cytokine production, altered metabolism and cytotoxic T lymphocytes (CTLs) killer functions, and eventual death of activated T cells. Bodies evolve coinhibitory pathways controllingTcell response magnitude and duration to limit tissue damage and maintain self-tolerance. However, tumor cells hijack these inhibitory pathways to escape host immune surveillance by overexpression of PD-L1. This provides the scientific rationale for clinical application of immune checkpoint inhibitors in oncology. The aberrantly high expression of PD-L1 in tumor microenvironment (TME) can be attributable to the "primary" activation of multiple oncogenic signaling and the "secondary" induction by inflammatory factors such as IFN-.. Clinically, antibodies targeting PD-1/PD-L1 reinvigorate the "exhausted" T cells in TME and show remarkable objective response and durable remission with acceptable toxicity profile in large numbers of tumors such as melanoma, lymphoma, and mismatch-repair deficient tumors. Nevertheless, most patients are still refractory to anti-PD-1/PD-L1 therapy. Identifying the predictive biomarkers and design rational PD-1-based combination therapy become the priorities in cancer immunotherapy. PD-L1 expression, cytotoxic T lymphocytes infiltration, and tumor mutation burden (TMB) are generally considered as the most important factors affecting the effectiveness of PD-1/PD-L1 blockade. The revolution in cancer immunotherapy achieved by PD-1/PD-L1 blockade offers the paradigm for scientific translation from bench to bedside. The next decades will without doubt witness the renaissance of immunotherapy.

Improvement of the anticancer efficacy of PD-1/PD-L1 blockade via combination therapy and PD-L1 regulation

Strategies targeting PD-L1 expression and associated opportunities for cancer combination therapy

Combination strategies with PD-1/PD-L1 blockade: current advances and future directions

Progress in PD-1/PD-L1 inhibitors combined with other approaches in the treatment of non-small cell lung cancer

PD-1/PD-L1 Checkpoint Inhibitors in Tumor Immunotherapy

Strategies to enhance the therapeutic efficacy of anti-PD-1 antibody, anti-PD-L1 antibody and anti-CTLA-4 antibody in cancer therapy

Immune Checkpoint Blockade in Cancer Immunotherapy: Mechanisms, Clinical Outcomes, and Safety Profiles of PD-1/PD-L1 Inhibitors

Application of PD-1 Blockade in Cancer Immunotherapy

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PD-L1 blockade

Regulation of PD-1/PD-L1 pathway and resistance to PD-1/PDL1 blockade

Post-translational regulations of PD-L1 and PD-1: Mechanisms and opportunities for combined immunotherapy

Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens

Generation, secretion and degradation of cancer immunotherapy target PD-L1

Emerging therapeutic frontiers in cancer: insights into posttranslational modifications of PD-1/PD-L1 and regulatory pathways

Roles of PD-1/PD-L1 Pathway: Signaling, Cancer, and Beyond.

PD-1 regulation in immune homeostasis and immunotherapy

Optimization of cancer immunotherapy on the basis of programmed death ligand-1 distribution and function

Regulatory mechanisms of immune checkpoints PD-L1 and CTLA-4 in cancer

Resistance to PD-1/PD-L1 blockade cancer immunotherapy: mechanisms, predictive factors, and future perspectives

Research progress of tumor targeted drug delivery based on PD-1/PD-L1

Predictive biomarkers and mechanisms underlying resistance to PD1/PD-L1 blockade cancer immunotherapy